Free Trial

IM Cannabis (IMCC) Competitors

IM Cannabis logo
$1.97 +0.02 (+1.03%)
Closing price 03:59 PM Eastern
Extended Trading
$1.98 +0.02 (+0.76%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMCC vs. LVTX, XLO, RNXT, NEUP, JSPR, OKUR, VRCA, DYAI, ELUT, and LIMN

Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include LAVA Therapeutics (LVTX), Xilio Therapeutics (XLO), RenovoRx (RNXT), Neuphoria Therapeutics (NEUP), Jasper Therapeutics (JSPR), OnKure Therapeutics (OKUR), Verrica Pharmaceuticals (VRCA), Dyadic International (DYAI), Elutia (ELUT), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry.

IM Cannabis vs. Its Competitors

IM Cannabis (NASDAQ:IMCC) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

LAVA Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -4.19%. IM Cannabis' return on equity of -59.80% beat LAVA Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-4.19% -59.80% -5.15%
LAVA Therapeutics N/A -106.29%-38.24%

LAVA Therapeutics has a consensus target price of $2.69, suggesting a potential upside of 77.23%. Given LAVA Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LAVA Therapeutics is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
LAVA Therapeutics
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

IM Cannabis has higher revenue and earnings than LAVA Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.44M0.26-$7.72M-$0.54-3.65
LAVA Therapeutics$11.98M3.33-$25.11M-$1.05-1.44

7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IM Cannabis has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

In the previous week, LAVA Therapeutics had 8 more articles in the media than IM Cannabis. MarketBeat recorded 10 mentions for LAVA Therapeutics and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.95 beat LAVA Therapeutics' score of 0.11 indicating that IM Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
IM Cannabis Positive
LAVA Therapeutics Neutral

Summary

IM Cannabis beats LAVA Therapeutics on 8 of the 15 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

MetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$10.23M$10.68B$6.11B$10.47B
Dividend YieldN/A1.91%5.73%4.77%
P/E Ratio-3.6520.5185.3627.36
Price / Sales0.2626.68607.44135.43
Price / CashN/A25.0737.4661.86
Price / Book1.913.4812.426.81
Net Income-$7.72M$208.83M$3.32B$276.80M
7 Day Performance-1.50%-0.29%1.01%0.27%
1 Month Performance2.07%3.71%10.75%8.31%
1 Year Performance-8.04%-4.01%76.20%35.60%

IM Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCC
IM Cannabis
0.6499 of 5 stars
$1.97
+1.0%
N/A-14.5%$10.23M$39.44M-3.65340Gap Up
LVTX
LAVA Therapeutics
1.8654 of 5 stars
$1.53
-0.6%
$2.69
+75.5%
-3.8%$40.51M$11.98M-1.4660Insider Trade
XLO
Xilio Therapeutics
1.9955 of 5 stars
$0.76
-2.2%
$3.00
+295.3%
-2.2%$40.22M$6.34M-1.0070
RNXT
RenovoRx
2.1885 of 5 stars
$1.09
+0.9%
$7.50
+588.1%
+9.0%$39.58M$40K-2.876
NEUP
Neuphoria Therapeutics
2.2003 of 5 stars
$16.05
-4.0%
$28.00
+74.5%
N/A$39.42M$15.65M0.00N/A
JSPR
Jasper Therapeutics
3.4165 of 5 stars
$2.51
+4.6%
$25.63
+920.9%
-84.9%$39.01MN/A-0.4220
OKUR
OnKure Therapeutics
3.742 of 5 stars
$2.89
+0.3%
$32.33
+1,018.8%
-84.5%$38.97MN/A0.00N/A
VRCA
Verrica Pharmaceuticals
3.9302 of 5 stars
$4.11
+0.2%
$60.00
+1,359.9%
-71.1%$38.73M$7.57M-0.5040News Coverage
DYAI
Dyadic International
3.2458 of 5 stars
$1.05
-1.9%
$6.00
+471.4%
+0.0%$38.72M$3.49M-5.537
ELUT
Elutia
3.1583 of 5 stars
$0.89
-2.0%
$7.00
+689.1%
-76.3%$38.36M$24.38M-0.84180News Coverage
LIMN
Liminatus Pharma
N/A$1.35
-4.3%
N/AN/A$38.16MN/A0.00N/APositive News

Related Companies and Tools


This page (NASDAQ:IMCC) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners